Pharma Mar, S.A. (BME: PHM)
Health Care · Biotechnology · ES
€68.60
-1.65% today · -20.7% 1Y
Pharma Mar, S.A. (BME: PHM) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.35B and employs 505 people.
Over the last twelve months the share price has lost 20.7%, trading between 64.00 and 105.20.
Tweenvest scores Pharma Mar, S.A. across four factors: quality 73/100, value 51/100, growth 8/100, dividend 26/100. Its strongest factor is quality.
PHM price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.35B
- Revenue (TTM)
- $249.79M
- P/E
- 22.41
- EPS
- 3.11
- Dividend yield
- 1.42%
- Beta (5Y)
- 0.47
- 52-week high
- €105.20
- 52-week low
- €64.00
- Avg volume (3M)
- —
- Shares outstanding
- 17.34M
- Employees
- 505
- Next earnings
- —
About Pharma Mar, S.A.
Pharma Mar, S.A., a biopharmaceutical firm established in 1986 and headquartered in Madrid, Spain, is dedicated to the research, development, production, and global sale of marine-derived bioactive compounds. Its primary focus is oncology, with operations spanning Spain, Italy, Germany, Ireland, the wider European Union, the United States, and other international markets. The company's activities are organized into three key segments: Oncology, Diagnostics, and RNA interference. Among its developed and commercialized treatments are Yondelis, prescribed for soft tissue sarcomas and ovarian cancer; Aplidin, targeting multiple myeloma; and Zepzelca, used for patients with small cell lung cancer. Furthermore, Pharma Mar is advancing PM14, currently in Phase II clinical trials for various solid tumors. Beyond pharmaceuticals, the company manufactures and markets diagnostic kits and is involved in creating therapeutic drugs designed to reduce or silence gene expression.
- ISIN
- ES0169501022
- Founded
- 1986
- Listed since
- Sep 8, 2000
- Exchange
- Bolsas y Mercados Espanoles
- Currency
- EUR
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| GNI Group Ltd.TSE: 2160 | $1.38B | ¥3,305.00 | +1.85% |
| Inhibrx Biosciences, Inc.NasdaqGS: INBX | $1.37B | $92.76 | -0.64% |
| Ascentage Pharma Group InternationalSEHK: 6855 | $1.37B | HK$29.20 | +1.04% |
| AnaptysBio, Inc.NasdaqGS: ANAB | $1.36B | $46.21 | +1.23% |
| Vcanbio Cell & Gene Engineering Corp., LtdSHSE: 600645 | $1.32B | CN¥19.41 | +3.58% |
| Vitrolife AB (publ)OM: VITR | $1.30B | Skr93.10 | -3.32% |
| Bio-Thera Solutions, Ltd.SHSE: 688177 | $1.30B | CN¥21.03 | +0.96% |
| Liaoning Chengda Biotechnology Co., Ltd.SHSE: 688739 | $1.29B | CN¥21.02 | +1.94% |
Figures last refreshed Oct 4, 2026.